| Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis M Walsh, PA Merkel, CA Peh, WM Szpirt, X Puéchal, S Fujimoto, ... New England Journal of Medicine 382 (7), 622-631, 2020 | 610 | 2020 |
| Effects of allopurinol on the progression of chronic kidney disease SV Badve, EM Pascoe, A Tiku, N Boudville, FG Brown, A Cass, P Clarke, ... New England Journal of Medicine 382 (26), 2504-2513, 2020 | 347 | 2020 |
| A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD) ND Toussaint, E Pedagogos, NM Lioufas, GJ Elder, EM Pascoe, ... Journal of the American Society of Nephrology 31 (11), 2653-2666, 2020 | 65 | 2020 |
| The β-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial MA Roberts, HL Pilmore, FL Ierino, SV Badve, A Cass, AX Garg, NM Isbel, ... American Journal of Kidney Diseases 67 (6), 902-911, 2016 | 53 | 2016 |
| A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin … DW Johnson, EM Pascoe, SV Badve, K Dalziel, A Cass, P Clarke, ... American Journal of Kidney Diseases 65 (1), 49-57, 2015 | 44 | 2015 |
| Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial MG Collins, MA Fahim, EM Pascoe, CM Hawley, DW Johnson, ... The Lancet 402 (10396), 105-117, 2023 | 27 | 2023 |
| Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals P Natale, T Gutman, M Howell, K Dansie, CM Hawley, Y Cho, AK Viecelli, ... Nephrology Dialysis Transplantation 35 (5), 755-764, 2020 | 26 | 2020 |
| Association between serum hepcidin‐25 and primary resistance to erythropoiesis‐stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial J Gummer, R Trengove, EM Pascoe, SV Badve, A Cass, P Clarke, ... Nephrology 22 (7), 548-554, 2017 | 23 | 2017 |
| Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial … MG Collins, MA Fahim, EM Pascoe, KB Dansie, CM Hawley, PA Clayton, ... Trials 21, 1-19, 2020 | 20 | 2020 |
| Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network AT Morrish, CM Hawley, DW Johnson, SV Badve, V Perkovic, ... Kidney International 85 (1), 23-30, 2014 | 20 | 2014 |
| Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops T Gutman, A Tong, M Howell, K Dansie, CM Hawley, JC Craig, ... Nephrology Dialysis Transplantation 35 (9), 1585-1594, 2020 | 16 | 2020 |
| Conducting clinical trials during the COVID-19 pandemic—a collaborative trial network response L Robison, Y Cho, AK Viecelli, DW Johnson, CM Hawley, A Valks, ... Trials 22, 1-9, 2021 | 14 | 2021 |
| Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial SV Badve, L Zhang, JS Coombes, EM Pascoe, A Cass, P Clarke, P Ferrari, ... Canadian journal of kidney health and disease 2, 66, 2015 | 14 | 2015 |
| ‘Knowledge is power’: A framework for partnering with consumers in developing and delivering a scientific meeting in nephrology E Duncanson, K Dansie, T Gutman, A Tong, M Howell, S Jesudason, ... Nephrology 25 (5), 379-383, 2020 | 13 | 2020 |
| Targeted education ApproaCH to improve peritoneal Dialysis outcomes (TEACH-PD): a feasibility study JSF Chow, K Adams, Y Cho, P Choi, KL Equinox, AE Figueiredo, ... Peritoneal Dialysis International 40 (2), 153-163, 2020 | 11 | 2020 |
| The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial L Zhang, J Coombes, EM Pascoe, SV Badve, K Dalziel, A Cass, P Clarke, ... Redox Report 21 (1), 14-23, 2016 | 10 | 2016 |
| Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT D Jayne, M Walsh, PA Merkel, CA Peh, W Szpirt, X Puéchal, S Fujimoto, ... National Institute for Health and Care Research, 2022 | 6 | 2022 |
| PEXIVAS Investigators M Walsh, PA Merkel, CA Peh, WM Szpirt, X Puéchal, S Fujimoto, ... Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis 622 …, 0 | 6 | |
| Implementation strategies for high impact nephrology trials: the end of the trial is just the beginning DM Reidlinger, DW Johnson, JC Craig, SP McDonald, AR Mallard, ... Kidney International 102 (6), 1222-1227, 2022 | 5 | 2022 |
| Baseline characteristics and representativeness of participants in the BEST-fluids trial: a randomized trial of balanced crystalloid solution versus saline in deceased donor … MG Collins, MA Fahim, EM Pascoe, CM Hawley, DW Johnson, ... Transplantation Direct 8 (12), e1399, 2022 | 5 | 2022 |
